Completed OBSERVATIONAL NCT00245310

Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure

Sponsor: Heidelberg University

Conditions Acute Liver Failure Liver Cirrhosis

Interventions Indocyangreen (ICG) clearance

Updated 6 times since 2017 Last updated: Oct 8, 2010 Started: Oct 31, 2005 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Acute Liver Failure and Liver Cirrhosis and is currently completed. Heidelberg University leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heidelberg University

Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany